Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
(NQ:
KNSA
)
47.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
< Previous
1
2
3
4
5
Next >
Kiniksa (KNSA) Q1 2026 Earnings Transcript
↗
June 01, 2026
Kiniksa (KNSA) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Screens as Affordable Growth
↗
May 29, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (KNSA) Shows Explosive Potential with Perfect Minervini Trend Template and 460% EPS Growth
↗
May 25, 2026
Via
Chartmill
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
↗
May 23, 2026
Kiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline
Via
MarketBeat
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
↗
April 28, 2026
The biotech delivered a beat-and-raise first quarter.
Via
The Motley Fool
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges on Q1 Earnings Beat and Raised ARCALYST Guidance
↗
April 28, 2026
Via
Chartmill
Topics
Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surfaces as a GARP Opportunity with a Growth Rating of 8
↗
April 25, 2026
Via
Chartmill
Gapping stocks in Tuesday's session
↗
April 28, 2026
Via
Chartmill
What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge
↗
April 17, 2026
This biotech innovator in inflammatory disease therapies reported a notable insider sale amid strong revenue growth and recent stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Kiniksa Pharmaceuticals (KNSA) Shows High Growth Momentum and Technical Breakout Potential
↗
April 14, 2026
Kiniksa Pharmaceuticals (KNSA) exemplifies a high-growth momentum stock with strong fundamentals and a positive technical setup for potential breakout.
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum
↗
April 03, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a Compelling Growth and Technical Setup
↗
March 30, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup
↗
March 23, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment
↗
March 20, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup
↗
March 05, 2026
Via
Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup
↗
March 02, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing
↗
February 27, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment
↗
February 25, 2026
Via
Chartmill
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines Strong Growth with Bullish Technical Setup
↗
February 10, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with Strong Technical Setup
↗
January 29, 2026
Via
Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the High-Growth Momentum and Trend Template Strategy
↗
December 13, 2025
KNSA stock meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including surging EPS and revenue.
Via
Chartmill
Earnings Scheduled For October 28, 2025
↗
October 28, 2025
Via
Benzinga
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Combines Technical Strength and Fundamental Growth Momentum
↗
November 20, 2025
KNSA stock shows strong technical momentum per the Minervini Trend Template and impressive fundamental growth with 421% EPS growth.
Via
Chartmill
What to Expect from Kiniksa Pharmaceuticals's Earnings
↗
October 27, 2025
Via
Benzinga
5 Analysts Have This To Say About Kiniksa Pharmaceuticals
↗
October 17, 2025
Via
Benzinga
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen
↗
October 08, 2025
Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance.
Via
Chartmill
What Analysts Are Saying About Kiniksa Pharmaceuticals Stock
↗
September 29, 2025
4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Via
Benzinga
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup
↗
September 24, 2025
Kiniksa Pharmaceuticals (KNSA) shows explosive EPS growth of 483% and strong technicals, trading near 52-week highs in a consolidation pattern that suggests a potential breakout.
Via
Chartmill
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
